Keros Therapeutics
Stock Forecast, Prediction & Price Target
Keros Therapeutics Financial Estimates
Keros Therapeutics Revenue Estimates
Keros Therapeutics EBITDA Estimates
Keros Therapeutics Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $20.1M N/A | $0 -100% | $151K 0% | Avg: $5.68M Low: $5.06M High: $7.48M avg. 3664.17% | Avg: $30.48M Low: $27.14M High: $40.16M avg. 436.33% | Avg: $138.89M Low: $123.69M High: $182.97M avg. 355.60% | Avg: $313.05M Low: $278.80M High: $412.41M avg. 125.39% |
Net Income
% change YoY
| $-58.74M N/A | $-104.68M -78.19% | $-152.99M -46.15% | Avg: $-201.26M Low: $-194.35M High: $-133.98M avg. -31.54% | Avg: $-200.61M Low: $-223.50M High: $-60.95M avg. 0.32% | Avg: $-107.81M Low: $-152.29M High: $-92.47M avg. 46.25% | Avg: $-37.73M Low: $-53.30M High: $-32.36M avg. 65.00% |
EBITDA
% change YoY
| $-56.72M N/A | $-104.67M -84.52% | $-152.17M -45.37% | Avg: $-1.11M Low: $-1.46M High: $-991.86K avg. 99.26% | Avg: $-5.97M Low: $-7.86M High: $-5.31M avg. -436.33% | Avg: $-27.21M Low: $-35.85M High: $-24.23M avg. -355.60% | Avg: $-61.33M Low: $-80.80M High: $-54.62M avg. -125.39% |
EPS
% change YoY
| -$2.52 N/A | -$4.15 -64.68% | -$5.2 -25.30% | Avg: -$5.18 Low: -$6.6 High: -$4.55 avg. 0.44% | Avg: -$4.96 Low: -$7.59 High: -$2.07 avg. 4.20% | Avg: -$3.66 Low: -$5.17 High: -$3.14 avg. 26.16% | Avg: -$1.28 Low: -$1.81 High: -$1.1 avg. 65.00% |
Operating Expenses
% change YoY
| $76.47M N/A | $107.70M 40.84% | $170.09M 57.91% | Avg: $266.08M Low: $236.97M High: $350.53M avg. 56.43% | Avg: $1.42B Low: $1.27B High: $1.88B avg. 436.33% | Avg: $6.50B Low: $5.79B High: $8.56B avg. 355.60% | Avg: $14.65B Low: $13.05B High: $19.30B avg. 125.39% |
FAQ
What is Keros Therapeutics stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 20.00% in 2025-2028.
We have gathered data from 8 analysts. Their low estimate is -194.35M, average is -201.26M and high is -133.98M.
What is Keros Therapeutics stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 1145.37% in 2025-2028.
We have gathered data from 6 analysts. Their low revenue estimate is $5.06M, average is $5.68M and high is $7.48M.
What is Keros Therapeutics stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 23.95% in 2025-2028.
We have gathered data from 8 analysts. Their low earnings per share estimate is -$6.6, average is -$5.18 and high is $-4.55.
What is the best performing analyst?
In the last twelve months analysts have been covering Keros Therapeutics stock. The most successful analyst is Kelly Shi.